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Introduction
Ischemic stroke is a life-threatening disorder, with no effective therapy except for intravascular thrombolysis with recombinant tissue plasminogen activator (rtPA) or, in some instances, surgical removal of the obstructing blood clot with interventional devices (Donnan et al., 2008; Zaleska et al., 2009 ). However, the risk of hemorrhage and a restrictive 3-4.5 hour treatment window (Hacke et al., 2008) reduces the pool of patients eligible for rtPA to only 5-8%. Despite continued improvement in our understanding of mechanisms underlying ischemic damage and, the identification of numerous neuroprotective agents effective in animal models, no agent has yet demonstrated significant benefit in the clinic (O'Collins et al., 2006; Savitz and Fisher, 2007; Zaleska et al., 2009) . Hence, the development of stroke therapeutics remains a daunting challenge, as does the urgent need for new agents.
The Src family of non-receptor protein tyrosine kinases, (PTKs), coordinate a broad spectrum of physiological responses including extracellular signals derived from growth factor and cytokine receptors, G-protein-coupled receptors, ion channels and cell-cell and cell-matrix adhesion signaling molecules (Thomas and Brugge, 1997) . Five members of the Src family PTKs; Src, Fyn, Yes, Lck and Lyn are highly expressed in platelets and in the mammalian CNS. Src family kinases have been shown to be activated following global ischemia and to potentiate the activity of NMDA receptors (Salter and Kalia, 2004; Guo et al., 2006) and voltage-gated calcium and potassium channels (Cataldi et al., 1996; Fadool et al., 1997) all known contributors to ischemic cell death.
A major role for Src kinase in VEGF-induced vascular permeability (VP) has also been established (Eliceiri et al., 1999) . Focal cerebral ischemia in rodents (Plate et al., 1999; Zhang and Chopp, 2002) and ischemic stroke in humans (Issa et al., 1999) 
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5 a key promoter of VP leading to breakdown of the BBB and clinical deterioration (Croll and Wiegand, 2001 ). Antagonism of VEGF reduces stroke-induced injury and edema (van Bruggen et al., 1999) while administration of recombinant VEGF shortly after stroke increases BBB leakage and exacerbates ischemic injury (Zhang and Chopp, 2002) . Paul et al., (Paul et al., 2001) first demonstrated that mice deficient in Src or Yes, but not Fyn, did not exhibit VP in response to VEGF administration and were resistant to ischemic injury while administration of Src inhibitors PP1 or PP2 to wild type animals, reduced ischemic injury when assessed within the first 24 hr (Paul et al., 2001; Lennmyr et al., 2004; Weis et al., 2004a) . These data established proof of concept for achieving neuroprotection by targeting Src kinase. In addition, both an earlier Src inhibitor, PP1, and the dual Src/Abl inibitor SKI-606 (Bosutinib) , undergoing clinical trials for the treatment of cancer, were shown to block VEGF-induced endothelial barrier break down and reduce injury in a mouse model of myocardial ischemia (Weis et al., 2004b) and to suppress VEGF-mediated tumor cell extravasation and metastasis (Weis et al., 2004a) .
In the present study we report a systematic evaluation of the neuroprotective profiles of SKI-606 and the novel Src inhibitor, SKS-927, both with potency superior to that of PP1. Our results demonstrate that both agents block VEGF-mediated signaling in endothelial cells, penetrate into the CNS upon intravenous administration, inhibit post-ischemic Src kinase activation and BBB leakage, and provide robust and long-lasting neuroprotection in two focal cerebral ischemia models, with a clinically relevant therapeutic window. Our animal efficacy studies were designed to mimic clinical circumstances and the results obtained strongly support the use of SKI-606 and SKS-927 in clinical trials for stroke.
This article has not been copyedited and formatted. The final version may differ from this version. Adult male Wistar rats (Charles River, Wilmington, MA; 290-310g) were randomly allocated to treatment groups. Researchers blinded to treatment allocation performed stroke-inducing surgeries and conducted assessments of neurological deficits, infarct volume and histology.
Drug profiles and administration. )amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile) and )amino]-6-methoxy-7-[4-(4-methypiperzin-1-yl)but-1-ynyl]-3-quinolinecarbonitrile) (see Fig. 1A for structures) were synthesized as previously described (Boschelli et al., 2001; . Potency of SKI-606 was 30-fold higher (IC 50 of 1.2 nM) than that of PP1 (1-tert-Butyl-3-p-tolyl-1H-pyrazolo [3,4-d] pyrimidin-4-ylamine; 35 nM), in an ELISA-based Src enzymatic assay, while in a LANCE -based enzymatic assay, IC 50 values for SKI-606 and SKS-927 were 3.9 nM and 3.8 nM, respectively. In a cell proliferation assay employing Src transformed rat fibroblasts, IC 50 values for SKI-606, SKS-927 and PP1 were 100 nM, 73 nM (Boschelli et al., 2001; Rix et al., 2009; Bantscheff et al., 2007; Puttini et al., 2006) Measurement of total and phosphorylated Src (pY418 Src) kinase levels in blood and brain. At various time intervals following systemic treatment with SKS-927, control and ischemic (tMCAO) animals were anesthetized with isoflurane and 1 ml of blood was drawn from the heart and centrifuged to obtain platelet-enriched fraction. The ipsilateral cerebral cortex and striatum were removed from a 6 mm mid-forebrain section and homogenized in 1:10 (w/v) icecold RIPA buffer (Sigma, St. Louis, MO) containing protease (Complete Mini, Roche, Indianapolis, IN) and phosphatase inhibitors (cocktail set #2, Calbiochem, La Jolla, CA). Src levels were measured using total Src and pY418-Src (autophosphorylated) ELISA Kits (BioSource International Inc., Camarillo, CA) following manufacturer's recommended protocols.
Src concentrations were calculated according to appropriate standard curves run within each assay. pY418-Src concentration (U) was normalized to total Src level (ng) in each sample and presented as mean ratios of pY418-Src/total Src.
Transient middle cerebral artery occlusion (tMCAO). Rats were anesthetized with 3%
isoflurane in a mixture of 70% nitrous oxide and 30% oxygen through a nose cone. Core body temperature was maintained at 37 o C throughout the surgery using a heating lamp. Transient MCAO was induced for 90 min using intraluminal suture according to the established procedure (Longa et al., 1989) . Briefly, an 18 mm length of 4-0 nylon monofilament with a flame-rounded tip was inserted into the external carotid artery and advanced into the internal carotid to occlude the origin of the MCA. Ninety minutes later rats were re-anesthetized, the suture withdrawn, This article has not been copyedited and formatted. The final version may differ from this version. (Bederson et al., 1986 ) and a maximum score of 5 at 90 min post-induction of tMCAO was a criterion for inclusion in the study. SKI-606, SKS-927 or vehicle were administered at various time intervals (0.5-6.0 hrs) after the induction of stroke at the doses indicated in figure legends (n=16/group). Core body temperature was measured within 30 min of drug dosing to monitor for potential drug effect on temperature. Sham-operated controls were subjected to identical surgical procedures but without advancement of the monofilament into the MCA branching point. Rats were sacrificed at 48 hrs post-tMCAO. Animals that died before 48 hrs or displayed hemorrhage upon harvesting the brain were excluded.
Permanent middle cerebral artery occlusion (pMCAO).
A craniotomy was performed under isoflurane anesthesia followed by electrocauterization of the distal portion of the MCA under a stereomicroscope according to procedure established by Chen et al., (Chen et al., 1986) . Core body temperature was maintained at 37 o C throughout the surgery using a heating lamp. This procedure results in a consistent infarction in the area of sensorimotor cortex governing the forelimb and hindlimb function and, an excellent survival of animals allows for a long-term assessment of neurological outcomes. Sham surgery included craniotomy without cauterization of the MCA. SKI-606, SKS-927 (10 mg/kg i.v.) or vehicle was administered at time intervals indicated in figure legends. In one study, animals (n=12/group) were sacrificed at 48 hr postinduction of pMCAO for measurement of infarct volume. In a second study, animals (n=10/group) were subjected to testing of sensorimotor and reflex deficits at 3-day intervals for 3 This article has not been copyedited and formatted. The final version may differ from this version. Infarct volume analysis. After sacrifice, brains were extracted and 2 mm coronal sections were cut starting at 4 mm from the frontal pole using a rat brain matrix (Stoeling, Wood Dale, IL).
Sections were stained by immersion in a 2% solution of 2,3,5-triphenyl tetrazolium chloride (TTC) at 37 o C for 10 min and then in 10% neutral formalin for preservation. Digitized images of sections were collected using the MCID image analysis system (Interfocus Imaging, Ltd., England), and the area of infarct determined for each slice. Total infarct volume was calculated by multiplying a sum of areas by the distance between them in mm.
This article has not been copyedited and formatted. The final version may differ from this version. Evans Blue extravasation. The integrity of the blood brain barrier (BBB) was assessed by measuring extravasation of Evans Blue dye into the brain parenchyma. A 2% solution of Evans Blue in saline was administered i.v. at a volume of 4 ml/kg at 4 or 22 hr post-induction of tMCAO. Two hr later, rats were anesthetized with isoflurane and perfused with 40 ml of saline through the left ventricle of the heart. Brains were removed and either sliced into 2 mm coronal sections for photography or the striatum and cortex were dissected, weighed, and Evans Blue content measured by fluorometry (Belayev et al., 1996) .
Immunohistochemistry. Three days following induction of tMCAO, vehicle and SKS-927
(10mg/kg i.v.) treated rats (n=4 /group) were anesthetized with isoflurane and perfused transcardially with PBS, followed by 100 ml of 4% paraformaldehyde. Brains were post-fixed This article has not been copyedited and formatted. The final version may differ from this version. Brain penetration of PP1 was not assessed in our studies, however, its reported efficacy in rodent stroke models upon i.p. administration (Paul et al., 2001) , suggests this compound is crossing the BBB.
As the phosphorylation of Src at Y418 within the activation loop of the kinase domain is required for full activation (Sun et al., 1998) , the level of pY418 Src in relation to total Src is therefore a good measure of its activation state. To evaluate the in vivo inhibitory effects of SKI-606 and SKS-927 on Src activation state in the brain, either agent was administered to naive rats as a single i.v. bolus at 10 or 30 mg/kg and cortical lysates were assayed 1 hr post-treatment. A 31% and 61% reduction, and 64% and 84% reduction in pSrc levels were found for SKS-927 and SKI-606, respectively (Fig.1B) .
This article has not been copyedited and formatted. The final version may differ from this version. As shown in Fig 1C, intravenous infusion of SKS-927 resulted in a dose-proportional and longlasting reduction of pY418-Src levels in platelet enriched blood fraction. At the doses 1, 10 and 30 mg/kg of SKS-927, Src autophosphorylation was inhibited by about 50%, 80%, and 100%, respectively, 2 hr after initiation of infusion, and remained at similar levels 4 hr post-infusion.
After 6 to 8 hr post-infusion, pSrc levels returned to baseline values in animals receiving 1 and 10 mg/kg dose, while at 30 mg/kg dose, pSrc levels were still reduced by 50% at 8 hr postinfusion. These results indicate long-lasting inhibition of Src kinase in blood following an i.v.
administration of a Src inhibitor.
SKS-927 abolishes ischemia-induced activation of Src kinase in the brain. To investigate whether focal ischemia induces activation of Src kinase in the brain, and if that activation could
be inhibited by systemic administration of SKS-927, we evaluated the temporal profile of Src activation during the initial 6-hour period following induction of stroke. Four groups of animals were used in this study: (i) naive (control), (ii) sham-operated, (iii) subjected to 90 min tMCAO with vehicle administration as an i.v. bolus at reperfusion time, and, (iv) subjected to 90 min tMCAO followed by administration of a single i.v. bolus of 10 mg/kg of SKS-927. Sham surgery did not affect pSrc levels in the cortex or striatum. A 2 to 4-fold increase in the level of activated Src kinase, sustained for 6 hr post-induction of tMCAO was observed in ischemic striatum (Fig. 1D) . Following SKS-927 treatment (10mg/kg i.v.) this increase in pSrc levels was dramatically reduced by 75% and 60% at 2 and 6 hr, respectively. In cortical lysates derived from ischemic animals, elevation of activated Src did not reach statistical significance.
However, following SKS-927 treatment, significant reduction in cortical pY418-Src level was found 6 hr post-induction of tMCAO, with a trend towards lowered pY418 Src levels observed at rescue was inhibited by 17%, while PP3, an inactive analog of PP1, had no effect. SKI-606, at concentrations of 30 or 300 nM blocked VEGF effects in HUVECs by 93 % and 100%, respectively ( Fig. 2A) . In the presence of the same concentrations of SKS-927, the VEGFmediated anti-apoptotic effects were reduced by 37% and 70%, respectively. These results demonstrate that both agents interfere with Src-dependent VEGF-mediated signaling in human endothelial cells with efficacy and potency superior to that of PP1.
The effect of Src inhibition on cerebral ischemia-induced BBB permeability is shown in Fig. 
2B. In vehicle treated animals, a pronounced extravasation of Evans Blue was observed 6 hr
This article has not been copyedited and formatted. The final version may differ from this version. (Fig. 2C) . In addition to leukocytes, anti-OX-1 antibody recognizes also activated microglia, both markers of inflammatory respose in the brain.
Quantitative assessment of infiltrating leukocytes revealed a 62% reduction within the striatum following treatment with SKS-927 while the decrease in the total cortical cell count did not reach statistical significance (Fig. 2D) . OX-41 staining was absent in brain sections from naïve animals.
Protection against tMCAO. Treatment with SKI-606 30 min post-occlusion, at doses of 3, 10 or 30 mg/kg, significantly reduced infarct volume by 24%, 57 %, and 44 %, respectively ( Fig   3A) . No significant effects on blood pressure, heart rate, or body temperature were observed at these doses (data not shown). Initiation of treatment with SKI-606 at a dose of 10 mg/kg at 0.5, tMCAO resulted in a trend towards reducing infarct volume, these changes did not reach statistical significance. However, a significant reduction of neurological deficits was observed when treatment was delayed up to 6 hr, with the highest reduction of 67 % in the group of animals treated with a 3-hour window and strong trends at early dosing times (Fig. 3C ).
Ischemia-induced weight loss was significantly attenuated by SKI-606, when given up to 5 hr post tMCAO, whereas the 6-hr treatment window resulted in a non-significant trend (Fig. 3D) .
Based on the results obtained with SKI-606, evaluation of protective efficacy of SKS-927 in the tMCAO model was conducted with a 4 -hour post-occlusion window. No significant effects of SKS-927 on blood pressure, heart rate, or body temperature were observed at the doses of 10 and 30mg/kg iv (data not shown) except for a transient decrease of heart rate from 404 ± 30 beats per min to 300 ± 31 beats per min during the first 5min post i.v. administration of the 30 mg/kg dose.
SKS-927 treatment resulted in a dose-dependent reduction of infarct volume by 32% and 40% at the doses of 10 mg/kg and 30 mg/kg, respectively (Fig. 4 A and B) . In the same animals, a robust dose-dependent attenuation of neurological deficits was observed at all doses tested (Fig.   4C ). After 48 hr of recovery, neurological deficit scores were reduced by 35% in the 3 mg/kg and 10 mg/kg dose treatment groups, an effect comparable to that observed with 10 mg/kg of SKI-606 administered at 4 hr post-occlusion (45%; Fig. 3C ). Administration of SKS-927 at a dose of 30 mg/kg resulted in a 53% decrease in neurological deficit scores relative to vehicle treated animals (Fig. 4C) . When SKS-927 was administered as 1-hour i.v. infusion (10 mg/kg), outcome measures comparable to those obtained following a single i.v. bolus administration at the same dose were achieved (not shown). This indicates that the neuroprotection is driven by total exposure to agent over time (AUC) rather than peak plasma concentration, a finding of significance for designing potential clinical dosing paradigms.
This article has not been copyedited and formatted. The final version may differ from this version. Results from our studies show directly for the first time that focal ischemia with reperfusion induces activation of Src kinase in the area of ischemic core for at least 6 hr poststroke, with some up-regulation of activated Src in surrounding cortical areas. These data add to previous reports demonstrating an up-regulation of Src activity in a global ischemia model that mimics cardiac arrest rather than ischemic stroke (Zalewska et al., 2005; Guo et al., 2006) . Our results show that the focal ischemia-induced up-regulation of Src is significantly reduced throughout this 6-hour period following a single i.v. bolus of SKS-927. VEGF-mediated activation of Src is directly involved in several signaling pathways in endothelial cells affecting induction of VP, migration and anti apoptosis (Eliceiri et al., 1999; Abu-Ghazaleh et al., 2001 ). factor-driven and Src-dependent expression of VEGF, predominantly in microglia and astrocytes with a parallel up-regulation of VEGF receptors on the abluminal side of endothelial cells (Brillault et al., 2002; Zhang and Chopp, 2002) . VEGF is thought to act in a paracrine fashion on endothelial cells, and upon engaging its receptors, recruits Src kinase into a signaling complex mediating direct phosphorylation of cell-matrix or cell-cell adhesion proteins leading to reduced blood flow, tight junction disassembly, vascular leak and expansion of injury (Weis and Cheresh, 2005) . In a mouse myocardial infarction model, both SKI-606 and PP1 were shown to stabilize preformed Flk-cadherin-catenin complexes maintaining the integrity of endothelial cell contacts, reducing edema, infarct volume and improving functional recovery (Weis et al., 2004b) .
Disrupting VEGF-mediated Src activation with SKI-606 was also shown to suppress tumor cell extravasation and metastasis in vivo (Weis et al., 2004a) . Contrary to VEGF-induced VP in the acute phase, VEGF-mediated angiogenesis has been shown to contribute to recovery and remodeling of neurovascular units days after stroke (Croll and Wiegand, 2001; Zhang and Chopp, 2002) . However, angiogenesis is not affected by deficiency in individual Src family PTKs and Src deficient mice display normal angiogenic response to VEGF (Eliceiri et al., 1999) .
Of the many reasons attributable to the resounding failure of stroke therapeutics in the clinic, one clear shortcoming has been the lack of a suitable temporal treatment window poststroke. It is well known that most patients take many hours to reach hospitals and be treated, so investigational therapeutics need to be, at a minimum, effective hours rather than minutes poststroke in pre-clinical animal models. In this report, we have shown that Src inhibition supports a Among the few studies reporting protective effects of PP1 or PP2 in ischemic stroke, although within a short 24-hr period, only one study showed a comparable 6 hour therapeutic window in a mouse pMCAO model (Paul et al., 2001) . Preclinical efficacy profiles of are also superior to those of other recently reported Src inhibitors (Mukaiyama et al., 2007) , where treatment was started 15min post-stroke and no neurological recovery was evaluated; both findings with no clinical relevance. The predictive value of preclinical stroke models for a successful clinical trial has been poor even for agents that have shown efficacy when administered within several hours post-stroke (O'Collins et al., 2006, Savitz and Fisher, 2007) .
We believe that the combined profile of our Src inhibitors differentiate their therapeutic potential by demonstrating measurable temporal relationship between neuroprotective efficacy and drug-target engagement, a gap identified in most published pre-clinical studies (Feuerstein et al., 2008) .
Other cellular mechanisms, independent of VEGF and down-stream of Src, may also contribute to the neuroprotection against ischemic injury. Src kinase has been shown to This article has not been copyedited and formatted. The final version may differ from this version. (Salter and Kalia, 2004) and to activate calcium channels (Cataldi et al., 1996) . Blocking Src activity may therefore reduce NMDA function and modulate a variety of CNS proteins associated with propagation of excitotoxic injury in ischemic stroke. Supporting this notion is the fact that more robust neuroprotection is achieved by Src inhibition than by direct anti-VEGF therapies in acute stroke (Kimura et al., 2005) . Accordingly, 
